Michigan workers face higher health costs
Add Axios as your preferred source to
see more of our stories on Google.

Illustration: Annelise Capossela/Axios
Health cost increases for employers that offer benefits are forcing big changes in Michiganders' workplace coverage.
Why it matters: Health spending is putting a drag on the labor market and increasing affordability concerns for the 50.3% of Michiganders who get coverage through their employer.
By the numbers: Michigan employers are seeing a median 8% increase in health insurance premiums this year and expect another 8% next year, according to a survey from the Troy-based American Society of Employers.
- Employers can eat costs, redesign plans or change providers, but at many workplaces, more of the burden is shifting to employees.
- 75% of the companies surveyed increased how much employees pay.
- Many also have expanded high-deductible plans and increased deductibles.
Driving the news: A Gallagher benefits survey of more than 3,700 firms found 36% of the companies reported premium increases of 10% or more during their most recent renewal.
What they're saying: "The last two renewal cycles have been unlike anything we've ever seen before," said Robby White, Gallagher's U.S. benefits business line leader.
- "It's unsustainable, obviously. Every additional dollar that an employer spends on health care, they can't spend on their employees."
Zoom in: "In 2021, we paid $255, and now here in 2026 it's $455," Patti Eisenbraun, owner of Brown Iron Brewhouse in Royal Oak, told WLNS. "If small businesses could join in a group … they could get buying power, that would be helpful."
The big picture: The 2027 coverage year was already shaping up to be painful for many employers. Projections are showing premium spikes due to rising demand for health services, more chronic disease and increased use of drugs like GLP-1s.
- More people are being diagnosed with cancer at a younger age, and advanced treatments and related care can result in $10,000 a month in expenses or claims.
- Drug costs also are surging — and not just because of demand for GLP-1s. The high cost of specialty drugs for chronic or rare conditions is prompting companies to scrutinize the way formularies are designed and how well pharmacy benefit managers administer their benefits.

